Prodrug-like Quinone Containing Two Redox-Active Centers Induces Ferroptosis in Prostate Cancer Cells with Cytotoxic Action Partially Depending on NAD(P)H Quinone Dehydrogenase 1 (NQO1)
Aug 2026· ACS Omega· Vol 11, pp. 52411 - 52426· 0 citations· 119 references
Medicine
TL;DR
Overall, compound 4 highlights the potential of dual-redox quinone platforms to induce ferroptosis, providing a viable lead candidate for novel antineoplastic drug discovery in prostate cancer and other malignancies.
Abstract
Naphthoquinones are redox-active compounds with antitumor potential, often linked to NQO1 overexpression in cancer cells. This study evaluated the cytotoxic activity of two synthetic 1,4-naphthoquinones, compound 1 and its dual redox analog, compound 4, against NQO1-overexpressing DU-145 prostate cancer cells through integrated in vitro, enzymatic, and computational (docking and quantum) analyses. Compound 4 exhibited over 2-fold greater cytotoxicity against DU-145 cells compared to nontumor MRC-5 cells, while maintaining low hemolytic activity. Evidence of membrane damage, ROS generation, lipid peroxidation, and reversal by deferoxamine indicated ferroptosis induction by 4, whereas 1 triggered caspase-3-dependent apoptosis. Both caused ROS-mediated DNA damage attenuated by NAC. Docking and enzymatic assays confirmed partial dependence on NQO1, with 4 showing greater ROS production despite lower enzymatic activity. Overall, compound 4 highlights the potential of dual-redox quinone platforms to induce ferroptosis, providing a viable lead candidate for novel antineoplastic drug discovery in prostate cancer and other malignancies.
Overall, the cytotoxic effects of 7k on MV4-11 cells are attributed to the coordinated induction of ROS-mediated oxidative stress, G0/G1 cell cycle arrest, and caspase-dependent apoptosis, highlighting its promising antiproliferative potential.
Findings identify compound 9 as a promising multi-target quinoxaline-based agent with dual antiproliferative and anti-inflammatory activities, mediated through induction of mitochondrial apoptosis and modulation of oxidative stress and cytokine signaling pathways.
S. Alshawwa, Ghazi A. Bamagous, Hatem A. Sembawa et al.· RSC Advances· 0 citations
Overcoming drug resistance and minimizing off-target toxicity remain major challenges in cancer therapy. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a promising therapeutic target. Natural chalcones exhibit antitumor properties linked to oxidative stress indu...
Xin-Yue Bi, Haifu Sun, Kaihong Wang et al.· Bioorganic chemistry (Print)· 0 citations
DMC is identified as a thermosensitive inhibitor of SIRT3 and mechanistic insights into its potential to disrupt mitochondrial homeostasis for targeted cancer therapy are provided.
A50 may alleviated DOX-induced hepatotoxicity by activating the PI3K/AKT/HO-1 pathway to inhibit oxidative stress-driven pathological processes, including mitochondrial dysfunction, inflammation, and apoptosis.
Yu-Ting Zhao, Jing Zeng, Guang-Long Pang et al.· Frontiers in Pharmacology· 0 citations
NHE1 is identified as a key molecular target underlying the enhanced antitumor activity of methylated phenanthroline copper(II) complexes, and ligand methylation enhances the antitumor activity of copper(II) complexes and shifts their mechanism of action from DNA damage-driven cytotoxicity toward ROS-mediated apoptosis...
K. S. Muñoz Garzón, V. D. De Giusti, C. Y. Fernández et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.